Holen Sie sich die Stockscreener-App
7.58
1.63%
-0.11
Handel nachbörslich:
7.58
Schlusskurs vom Vortag:
$7.69
Offen:
$7.67
24-Stunden-Volumen:
50,283
Relative Volume:
0.51
Marktkapitalisierung:
$194.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.38M
KGV:
-5.3759
EPS:
-1.41
Netto-Cashflow:
$-15.54M
1W Leistung:
+2.37%
1M Leistung:
+24.42%
6M Leistung:
-6.72%
1J Leistung:
+48.04%
1-Tages-Spanne:
$7.45
$7.67
1-Wochen-Bereich:
$7.17
$7.77
52-Wochen-Spanne:
$4.44
$11.52
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Firmenname
Nuvectis Pharma Inc
Sektor
Branche
Telefon
360-837-7232
Adresse
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Vergleichen Sie NVCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
7.58 | 196.98M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Maxim Group | Buy |
| 2025-03-17 | Eingeleitet | Laidlaw | Buy |
| 2022-07-13 | Eingeleitet | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies - TipRanks
Nuvectis Pharma Starts Phase 1b Study With Osimertinib for Non-Small Cell Lung Cancer - marketscreener.com
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib - Investing.com India
Nuvectis Pharma announces the initiation of the phase 1b study of NXP900 in combination with osimertinib in patients with NSCLC - marketscreener.com
Nuvectis Pharma Announces the Initiation of the Phase 1b - GlobeNewswire
Precision Trading with Nuvectis Pharma Inc. (NVCT) Risk Zones - news.stocktradersdaily.com
Nuvectis Pharma Shares Gain Momentum on Analyst Backing and Clinical Progress - AD HOC NEWS
Published on: 2025-12-13 00:55:44 - earlytimes.in
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders - Yahoo Finance
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; individual investors who hold 44% profited and so did insiders - simplywall.st
Technical Reactions to NVCT Trends in Macro Strategies - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% HigherHere's What Happened - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% Higher – Here’s What Happened - Defense World
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com Australia
Will Nuvectis Pharma Inc. stock attract more institutional investors2025 Trade Ideas & Technical Buy Zone Confirmations - Newser
Will Nuvectis Pharma Inc. stock split attract more investors2025 Price Momentum & Scalable Portfolio Growth Ideas - Newser
Published on: 2025-11-30 11:27:46 - BỘ NỘI VỤ
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC - marketscreener.com
Nuvectis Pharma to Host a Virtual Key Opinion Leader - GlobeNewswire
Nuvectis Pharma to Host Key Opinion Leader Meeting on NXP900 Phase 1b Program in Advanced Solid Tumors - Quiver Quantitative
Trading the Move, Not the Narrative: (NVCT) Edition - news.stocktradersdaily.com
How Nuvectis Pharma Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
Nuvectis Pharma Inc. (NVCT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Nuvectis Pharma Inc. stock trendline breakdownPortfolio Risk Summary & Stock Market Timing Techniques - newser.com
How currency fluctuations impact Nuvectis Pharma Inc. stockEarnings Risk Summary & Weekly Watchlist for Consistent Profits - newser.com
What data driven models say about Nuvectis Pharma Inc.’s futureWeekly Gains Report & Reliable Volume Spike Trade Alerts - newser.com
Using RSI to spot recovery in Nuvectis Pharma Inc.Market Risk Report & Pattern Based Trade Signal System - newser.com
Predicting Nuvectis Pharma Inc. trend using moving averages2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
Top Analysts Predictions for Indobell Insulation Limited Stock Over 12 MonthsInsider Trading Activity & Free Unstoppable Trading Performance - earlytimes.in
What makes Nuvectis Pharma Inc. stock attractive to growth fundsMarket Volume Summary & Smart Investment Allocation Insights - newser.com
(NVCT) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Why Nuvectis Pharma Inc. stock remains undervaluedWeekly Market Outlook & Target Return Focused Stock Picks - newser.com
How Nuvectis Pharma Inc. stock performs in rate cut cycles2025 Market Sentiment & Stepwise Entry and Exit Trade Signals - newser.com
Director of Nuvectis Pharma Juan Sanchez Buys 20% More Shares - Yahoo Finance
Matthew Kaplan Acquires 11,000 Shares of Nuvectis Pharma (NASDAQ:NVCT) Stock - MarketBeat
Roth Capital Expects Lower Earnings for Nuvectis Pharma - Defense World
HC Wainwright Cuts Earnings Estimates for Nuvectis Pharma - Defense World
Nuvectis Pharma Executives Make Bold Moves with Major Stock Purchases! - TipRanks
Nuvectis Pharma director Sanchez buys $75k in NVCT stock By Investing.com - Investing.com Canada
Kaplan buys Nuvectis Pharma (NVCT) shares worth $64,240 By Investing.com - Investing.com South Africa
Insider Buying: Ron Bentsur Acquires Additional Shares of Nuvect - GuruFocus
Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvectis Pharma Inc-Aktie (NVCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
| Mosseri Marlio Charles | 10% Owner |
Jun 20 '25 |
Buy |
7.99 |
5,603 |
44,768 |
2,981,806 |
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
0.03%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):